vs
Commercial Bancgroup, Inc.（CBK）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
Commercial Bancgroup, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$23.1M vs $19.6M），Commercial Bancgroup, Inc.净利率更高（41.3% vs -177.4%，领先218.7%）
Commercial Bancgroup, Inc.是美国的一家区域性银行控股企业，为个人消费者、中小微企业及本地机构客户提供全品类零售与商业银行业务，核心服务涵盖存款账户、信贷产品、财富管理及定制化金融咨询方案。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CBK vs LAB — 直观对比
营收规模更大
CBK
是对方的1.2倍
$19.6M
净利率更高
CBK
高出218.7%
-177.4%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.1M | $19.6M |
| 净利润 | $9.5M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | — | -168.5% |
| 净利率 | 41.3% | -177.4% |
| 营收同比 | — | -11.5% |
| 净利润同比 | 9.7% | -28.8% |
| 每股收益（稀释后） | $0.69 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBKLAB
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | — | ||
| Q3 25 | $22.8M | $19.6M | ||
| Q2 25 | — | $21.8M | ||
| Q1 25 | — | $40.8M | ||
| Q3 24 | — | $22.1M | ||
| Q2 24 | — | $22.5M | ||
| Q1 24 | — | $45.5M |
净利润CBKLAB
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | — | ||
| Q3 25 | $9.5M | $-34.7M | ||
| Q2 25 | — | $-33.5M | ||
| Q1 25 | — | $-26.0M | ||
| Q3 24 | — | $-26.9M | ||
| Q2 24 | — | $-45.7M | ||
| Q1 24 | — | $-32.2M |
毛利率CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 53.8% | -168.5% | ||
| Q2 25 | — | -118.1% | ||
| Q1 25 | — | -80.8% | ||
| Q3 24 | — | -120.9% | ||
| Q2 24 | — | -134.5% | ||
| Q1 24 | — | -132.2% |
净利率CBKLAB
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | — | ||
| Q3 25 | 41.4% | -177.4% | ||
| Q2 25 | — | -153.7% | ||
| Q1 25 | — | -63.8% | ||
| Q3 24 | — | -122.0% | ||
| Q2 24 | — | -203.3% | ||
| Q1 24 | — | -70.6% |
每股收益（稀释后）CBKLAB
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | — | ||
| Q3 25 | $0.77 | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | — | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | $118.2M | — |
| 股东权益账面价值 | — | $399.7M |
| 总资产 | $2.3B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $154.8M | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务CBKLAB
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $245.2M | $399.7M | ||
| Q2 25 | — | $424.5M | ||
| Q1 25 | — | $454.6M | ||
| Q3 24 | — | $489.3M | ||
| Q2 24 | — | $510.3M | ||
| Q1 24 | — | $577.3M |
总资产CBKLAB
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.2B | $539.6M | ||
| Q2 25 | — | $557.0M | ||
| Q1 25 | — | $579.6M | ||
| Q3 24 | — | $681.5M | ||
| Q2 24 | — | $708.7M | ||
| Q1 24 | — | $777.7M |
负债/权益比CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $28.0M | $-22.2M | ||
| Q2 25 | — | $-20.7M | ||
| Q1 25 | — | $-30.3M | ||
| Q3 24 | — | $-27.9M | ||
| Q2 24 | — | $-39.0M | ||
| Q1 24 | — | $-62.5M |
自由现金流CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $26.5M | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 115.8% | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 6.7% | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% |
现金转化率CBKLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
